Director Dealing

BioVentix PLC

28 April 2026

 

Bioventix plc 

("Bioventix" or "the Company") 

Director Dealing 

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified today that on 27 April 2026 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 66 ordinary shares of 5 pence each in the Company ("Ordinary Shares"), at a price of 1,679 pence per Ordinary Share (the "Purchase"). The Ordinary Shares were purchased under a dividend reinvestment plan ("DRIP"). 

Following the Purchase, Bruce Hiscock has a beneficial interest in 1,666 Ordinary Shares, representing approximately 0.03 per cent. of the issued share capital of the Company. 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details. 

For further information please contact: 

Bioventix plc  Peter Harrison	Chief Executive Officer	Tel: [phone]
Cavendish  Geoff Nash / Elysia Bough  Nigel Birks / Harriet Ward	Corporate Finance  ECM	Tel: [phone]

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Bruce Hiscock
2.	Reason for the Notification
a)	Position/status	Chief Financial Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Bioventix Plc
b)	LEI	213800225MHX7LZQY108
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 5 pence each
	Identification code	GB00B4QVDF07
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	66 Ordinary Shares   1,679 pence
d)	Aggregated information:  ·     Aggregated volume  ·     Price	Purchase of 66 Ordinary Shares at 1,679 pence each
e)	Date of the transaction	27 April 2026
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

 

END